103
Participants
Start Date
July 31, 2012
Primary Completion Date
July 31, 2013
Study Completion Date
July 31, 2013
Alirocumab
1 mL subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using the autoinjector.
Ezetimibe
One over-encapsulated tablet orally once daily at approximately the same time of the day with or without food.
Placebo (for Alirocumab)
1 mL subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self--injection or by another designated person using the autoinjector.
Placebo (for Ezetimibe)
One capsule orally once daily at approximately the same time of the day with or without food..
Investigational Site Number 056601, Antwerp
Investigational Site Number 840602, Richmond
Investigational Site Number 840601, Cincinnati
Investigational Site Number 840603, Overland Park
Investigational Site Number 246601, Helsinki
Investigational Site Number 528602, Groningen
Investigational Site Number 528601, Rotterdam
Investigational Site Number 528603, Velp
Lead Sponsor
Regeneron Pharmaceuticals
INDUSTRY
Sanofi
INDUSTRY